Long-term study of bitopertin for EPP safety and benefit
Part of Digestive system, Genetic & congenital, Hormones & metabolism, Skin clinical trials.
This trial studies how safe and well bitopertin works over the long term for people with EPP. It mainly includes people who already finished an earlier bitopertin study, to keep tracking side effects and overall progress.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a confirmed EPP diagnosis and finished a prior bitopertin study phase (including the end-of-study visit)
- You are at least 12 years old when you sign up
- You meet the study’s body size limits (for under 18: at least 32 kg; for adults: BMI at least 18.5)
- If you could become pregnant (or your partner could), you must use very reliable birth control during the study and for at least 30 days after the last dose
- You can’t be pregnant (negative urine or blood pregnancy test if you could become pregnant)
- You must be able to follow study visits and instructions and sign consent (assent if needed)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at the long-term safety and benefits of taking etavopivat for people with sickle cell disease or thalassaemia who have already been helped by it in a previous trial. It aims to see if staying on the treatment continues to be safe and effective.
This program provides access to an experimental drug called bitopertin, which may help reduce the severe light sensitivity and pain caused by EPP or XLP. It's for people aged 12 and older who have not had success with other treatments.
This trial tests an oral medication called ciclopirox (ATL-001) to see if it can reduce skin sensitivity to sunlight in adults with CEP. It aims to improve the skin lesions caused by this rare disease.
This study tests an oral medication, PORT-77, to reduce pain and sensitivity to sunlight in people with EPP or XLP. It may help those who experience symptoms shortly after sun exposure.
This is a long-term study to check the safety of eplontersen over time in adults with transthyretin-mediated amyloid cardiomyopathy (ATTR-CM). It is mainly for people who already took the study medication before, or who joined an earlier related study and are doing well.
This is a first-in-human study to test an investigational drug called PSTB100 in healthy adults. The purpose is to see how the body handles the drug and to check for any side effects. Participation may help with future treatment development.
Hear when a new Erythropoietic Protoporphyria trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.